0000000000358728

AUTHOR

Ana Julve

showing 5 related works from this author

Abstract OT-13-06: Solti-1503 PROMETEO: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer

2021

Abstract Background Residual disease (RD) after standard neoadjuvant chemotherapy (NAC) is composed of drug resistant cells and associates with increased risk of relapse, especially in triple negative, HER2-positive, and highly proliferative Luminal tumors. Immunotherapy combinations can induce of specific anti-tumor immune responses, such as those mediated by T-cells, and which might represent an additional strategy for the control or elimination of residual tumor cells. Preliminary results in melanoma showed that the combination of T-VEC with an anti PD-L1 or anti CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent.…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentCancermedicine.diseaseClinical trialBreast cancerOncologyAtezolizumabInternal medicineMulticenter trialClinical endpointMedicinebusinessTalimogene laherparepvecCancer Research
researchProduct

Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of c…

2021

Abstract Introduction Sentinel lymph node biopsy (SLNB) after neoadjuvant therapy (NAT) in node-positive (N+) breast cancer patients at diagnosis remains a controversial issue, with no consensus on implementation or safety. Objectives We sought to assess the accuracy of SLNB after NAT in biopsy-proven N+ cases at diagnosis and the efficacy and accuracy of wire localization of the clipped node to improve results. Material and methods A cross-sectional diagnostic technique validation study in N+ patients following NAT was performed. The biopsy-proven affected lymph node was clipped at diagnosis. SLNB and axillary lymph node dissection (ALND) were performed in cases of clinical-radiological ly…

medicine.medical_specialtymedicine.medical_treatmentWire localizationSentinel lymph nodeBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerBiopsymedicineHumans030212 general & internal medicineLymph nodeNeoadjuvant therapyNeoplasm Stagingmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionMiddle Agedmedicine.diseaseSurgical InstrumentsNeoadjuvant Therapymedicine.anatomical_structureCross-Sectional Studies030220 oncology & carcinogenesisLymphatic MetastasisAxillaLymph Node ExcisionSurgeryNode (circuits)FemaleRadiologyLymph NodesSentinel Lymph NodebusinessThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
researchProduct

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and trea…

2021

Background Cancer is the second leading cause of mortality worldwide. Integrating different levels of care by implementing screening programmes, extending diagnostic tools and applying therapeutic advances may increase survival. We implemented a cancer fast-track programme (CFP) to shorten the time between suspected cancer symptoms, diagnosis and therapy initiation. Patients and methods Descriptive data were collected from the 10 years since the CFP was implemented (2009-2019) at the Clinico-Malvarrosa Health Department in Valencia, Spain. General practitioners (GPs), an oncology coordinator and 11 specialists designed guidelines for GP patient referral to the CFP, including criteria for br…

OncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsConstitutional symptomsPrimary careMedical Oncologyprimary careBreast cancerGeneral PractitionersInternal medicinemedicineearly diagnosticHumanscancerGastrointestinal cancerStage (cooking)Lung cancerReferral and ConsultationOriginal ResearchPrimary Health Carebusiness.industryCancermedicine.diseaseOncologyFast trackbusinessESMO open
researchProduct

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

2020

New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsHerpesvirus 1 HumanAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineBreast cancerClinical ProtocolsAtezolizumabInternal medicineClinical endpointHumansMedicineImmune Checkpoint InhibitorsTriple-negative breast cancerNeoplasm StagingOncolytic VirotherapyBiological ProductsClinical Trials as Topicbusiness.industryMelanomaGeneral MedicineImmune Checkpoint Proteinsmedicine.diseaseCombined Modality TherapyOncolytic virusClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemalebusinessTalimogene laherparepvecFuture Oncology
researchProduct

1624P Impact of the COVID-19 pandemic in the cancer fast-track programme

2021

Background: The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly in making timely cancer diagnosis. Our public health system has been concerned about potential delays leading to a higher proportion of patients with advanced stages. Our cancer diagnosis fast-track program (CFP) in the Clinic-Malvarrosa Health department in Valencia (Spain) is connecting primary care (PC) with different specialists to speed cancer diagnosis and treatment upon well founded suspicion. A 10-year evaluation of our CFP has recently been published. The aim of this analysis was to investigate the impact of the COVID-19 pandemic on the CFP. Methods: We analysed the programme…

Pediatricsmedicine.medical_specialtyReferralbusiness.industryIncidence (epidemiology)Public healthCancerHematologymedicine.diseaseArticleOncologyInterquartile rangePandemicMedicineFast trackbusinessLung cancerAnnals of Oncology
researchProduct